6533b85bfe1ef96bd12ba8e1
RESEARCH PRODUCT
Elección del agente oral más apropiado, en monoterapia o en combinación, en el paciente anciano con diabetes
F.c. Carramiñana BarreraJ. Navarro PérezX. Mundet Tudurísubject
Drugmedicine.medical_specialtyCombination therapybusiness.industryEndocrinology Diabetes and MetabolismInsulinmedicine.medical_treatmentmedia_common.quotation_subjectmedicine.diseasehumanitiesMetforminRegimenPharmacotherapyQuality of lifeDiabetes mellitusInternal MedicinemedicineIntensive care medicinebusinessmedicine.drugmedia_commondescription
The elderly patient with diabetes presents a series of features that we need to have in mind when considering drug therapy, such as quality of life, presence of chronic complications, major geriatric syndromes, and patient preferences. The limited evidence available due to the few studies performed in the elderly explains the limited existing recommendations in the most current clinical practice guidelines. Metformin is the drug of choice as monotherapy and its dosage should be adjusted to the degree of renal failure, a situation very common in the elderly. Other pharmacologic groups can also be used taking into account their limitations and contraindications. There is no consensus on what is the most appropriate combination therapy in the elderly when monotherapy fails. Any combination can be used provided that the indications and contraindications are considered. When insulin is necessary, benefits and risks of using insulin should be evaluated, using the simplest regimen adapted to the characteristics of the elderly and its environment.
year | journal | country | edition | language |
---|---|---|---|---|
2010-10-01 | Avances en Diabetología |